Can I Take Vitamin D with AOD-9604?

What Is AOD-9604 and Why Does the Supplement Question Matter?

AOD-9604 is a synthetic 16-amino-acid peptide corresponding to residues 176-191 of human growth hormone (HGH). It does not bind the GH receptor or stimulate IGF-1 production to any meaningful degree, which is the main reason it was separated from full-length GH for research purposes. Its proposed mechanism involves activating beta-3 adrenergic receptors in adipose tissue, stimulating lipolysis and inhibiting lipogenesis through a pathway that appears independent of insulin signaling. [1]

People using AOD-9604 frequently ask about supplements because compounded peptide protocols are rarely accompanied by the same clinical infrastructure as FDA-approved medications. Patients make their own supplementation decisions, and vitamin D is one of the most commonly self-administered supplements in the United States.

AOD-9604 Regulatory and Compounding Context

AOD-9604 is not FDA-approved for any indication in the United States. It is available through 503A compounding pharmacies for individualized patient prescriptions. The FDA's 2015 placement of AOD-9604 on the list of bulk drug substances that may not be used in compounding under section 503B was later distinguished from 503A use, but practitioners and patients should confirm current compounding pharmacy compliance before initiating any protocol. [2]

Why Vitamin D Status Matters in This Population

Patients pursuing peptide-based body-composition protocols often present with suboptimal vitamin D levels. A 2011 analysis published in Nutrition Research (N=4,495, NHANES data) found that 41.6% of U.S. Adults had serum 25-OHD concentrations below 20 ng/mL. [3] Deficiency is more prevalent among individuals with higher body-fat percentages, because vitamin D is sequestered in adipose tissue and its bioavailable fraction in serum falls as adiposity rises. [4] Since AOD-9604 is typically prescribed for adipose modulation, the very population using it carries elevated deficiency risk.

Is There a Pharmacokinetic Interaction Between AOD-9604 and Vitamin D?

No pharmacokinetic interaction between AOD-9604 and vitamin D has been identified in the peer-reviewed literature. The two compounds follow entirely different metabolic routes, and competition at absorption, distribution, or elimination steps is not mechanistically plausible.

AOD-9604 Pharmacokinetics

AOD-9604 is administered by subcutaneous injection or, in some compounded formulations, sublingually. As a short peptide, it is degraded by circulating peptidases and excreted renally as amino acid fragments. It does not undergo hepatic cytochrome P450 (CYP) metabolism, which eliminates a major category of drug-drug interaction risk. [1] Its plasma half-life in early human studies was approximately 30 minutes after subcutaneous dosing.

Vitamin D Pharmacokinetics

Vitamin D3 (cholecalciferol) absorbed from dietary or supplemental sources undergoes 25-hydroxylation in the liver via CYP2R1 and CYP27A1, followed by 1-alpha-hydroxylation in the kidney via CYP27B1 to produce the active hormone 1,25-dihydroxyvitamin D3 (calcitriol). [5] Because AOD-9604 does not interact with CYP2R1, CYP27A1, or CYP27B1, it does not alter vitamin D activation kinetics.

Vitamin D's fat-soluble nature means it is best absorbed with a meal containing dietary fat. AOD-9604, by contrast, is typically injected on an empty stomach to avoid competition with insulin signaling. These different timing considerations mean patients naturally separate the two compounds without any special scheduling effort required.

Absorption Competition

Vitamin D is absorbed in the small intestine via passive diffusion facilitated by bile acids. AOD-9604 given subcutaneously bypasses the gastrointestinal tract entirely. Even in sublingual AOD-9604 formulations, absorption occurs through the oral mucosa, not intestinal epithelium. No absorption competition exists. [5]

Is There a Pharmacodynamic Interaction?

Pharmacodynamic interactions occur when two compounds affect the same physiological target in an additive, synergistic, or antagonistic way. For AOD-9604 and vitamin D, the relationship is neither directly synergistic nor antagonistic. They operate through distinct receptor systems, but both compounds may influence overlapping downstream processes, particularly in bone metabolism and adipose-tissue regulation.

Beta-3 Adrenergic Signaling vs. VDR Signaling

AOD-9604 activates beta-3 adrenergic receptors (ADRB3) in adipose tissue. Vitamin D acts through the vitamin D receptor (VDR), a nuclear receptor expressed in more than 36 tissue types including adipose, bone, immune cells, and muscle. [6] These are distinct signaling pathways. No evidence suggests that activating the VDR blocks or amplifies ADRB3 signaling in fat tissue.

Bone Metabolism Overlap

Both compounds may independently influence bone-turnover markers. Vitamin D sufficiency is required for adequate calcium absorption (approximately 30-40% of dietary calcium is absorbed when vitamin D status is adequate, vs. Only 10-15% when deficient). [7] Some early AOD-9604 preclinical data suggested effects on osteoblast activity, though human evidence on bone endpoints remains limited. [1] Vitamin D adequacy before starting AOD-9604 is therefore a reasonable precaution to protect bone mineral density during any body-composition protocol that might shift calcium dynamics.

Adipose Tissue and Vitamin D

VDR is expressed in human adipocytes. A 2012 randomized controlled trial published in the American Journal of Clinical Nutrition (N=218) found that vitamin D3 supplementation at 3,332 IU/day for one year produced a modest but statistically significant reduction in fat mass compared to placebo in overweight adults (P<0.01). [8] This observation does not mean vitamin D potentiates AOD-9604, but it does suggest that both compounds may act on similar cellular compartments through different mechanisms, and that combined use is unlikely to produce opposing effects on body composition.

Dosing, Timing, and Practical Co-Administration

No dose-separation window is required when taking vitamin D alongside AOD-9604. The two compounds do not compete at any absorption or receptor site, and no clinical reports of adverse events from combined use have been published.

Recommended Vitamin D Dosing During Peptide Protocols

The Endocrine Society's 2011 clinical practice guideline on vitamin D deficiency defines deficiency as 25-OHD <20 ng/mL and insufficiency as 20-29 ng/mL, and recommends treatment doses of 50,000 IU vitamin D2 or D3 weekly for 8 weeks to correct deficiency, followed by maintenance of 1,500-2,000 IU daily. [9] Practitioners prescribing AOD-9604 should assess 25-OHD at baseline and target a serum level of 40-60 ng/mL, a range associated with optimal musculoskeletal and metabolic function in multiple observational datasets.

The following framework reflects how HealthRX clinicians approach vitamin D repletion during AOD-9604 protocols:

• Baseline 25-OHD <20 ng/mL: Initiate repletion at 50,000 IU vitamin D3 weekly for 8 weeks, then reassess.
• Baseline 25-OHD 20-29 ng/mL: Start maintenance at 2,000 IU daily; recheck at 12 weeks.
• Baseline 25-OHD 30-59 ng/mL: Continue current regimen or initiate 1,000-2,000 IU daily.
• Baseline 25-OHD >60 ng/mL: No supplementation change needed; recheck at 6 months.

This framework does not alter AOD-9604 dosing in any tier.

Timing Relative to AOD-9604 Injection

Most AOD-9604 protocols call for subcutaneous injection 30-60 minutes before the first meal of the day or before bed, on an empty stomach. Vitamin D3 supplements should be taken with the largest meal of the day to maximize fat-soluble absorption. In practice this means the two compounds are taken hours apart without any deliberate effort, which poses no clinical concern. [5]

Co-Factors to Consider With Vitamin D

Vitamin D repletion works best when magnesium status is adequate, because magnesium is a cofactor for the CYP enzymes that activate vitamin D. A 2018 study in The American Journal of Clinical Nutrition (N=180) demonstrated that magnesium supplementation significantly influenced 25-OHD and 1,25-dihydroxyvitamin D concentrations. [10] Patients on AOD-9604 protocols who are correcting vitamin D deficiency may benefit from concurrent magnesium glycinate 200-400 mg daily, particularly if dietary magnesium intake is low.

Vitamin K2 (menaquinone-7) is frequently co-administered with higher-dose vitamin D (above 2,000 IU daily) to direct calcium to bone rather than soft tissue. No interaction between vitamin K2 and AOD-9604 has been identified.

Safety Considerations and Monitoring

Both compounds are generally well-tolerated at standard doses, but AOD-9604's limited human trial data and vitamin D's potential toxicity at high doses mean that monitoring is not optional.

AOD-9604 Safety Profile

The most extensive published human safety data for AOD-9604 comes from an Australian Phase IIb trial (METAOD006, N=300) that evaluated oral AOD-9604 at doses up to 9 mg/day for 24 weeks. No significant adverse effects on glucose, insulin, lipids, IGF-1, or bone markers were observed compared to placebo. [11] Subcutaneous formulations, which are more common in current compounding practice, have a narrower published safety dataset, though injection-site reactions are the most frequently reported adverse event.

Vitamin D Toxicity Threshold

Vitamin D toxicity (hypervitaminosis D) producing clinically relevant hypercalcemia is rarely seen at serum 25-OHD levels below 150 ng/mL. The Institute of Medicine set the tolerable upper intake level for vitamin D at 4,000 IU/day for adults, though the Endocrine Society notes that doses up to 10,000 IU/day are unlikely to produce toxicity in most adults when monitored. [9] Serum calcium and 25-OHD should be checked at baseline and at 3 months when initiating repletion doses above 2,000 IU/day.

Parathyroid Hormone and Calcium Dynamics

Vitamin D deficiency causes secondary hyperparathyroidism: PTH rises to maintain serum calcium, and bone resorption accelerates. Correcting vitamin D deficiency reduces PTH and slows bone turnover. A 2009 meta-analysis in the British Medical Journal (22 RCTs, N=3,502) found that vitamin D supplementation with calcium reduced fracture risk by 12% compared to placebo or calcium alone (relative risk 0.88, 95% CI 0.78-0.99). [12] Monitoring a baseline PTH level is reasonable in any patient beginning a bone-adjacent protocol, including AOD-9604.

Recommended Monitoring Panel

The following labs are reasonable at baseline and at 12 weeks for a patient co-administering AOD-9604 and vitamin D:

| Lab | Baseline | 12 Weeks | |---|---|---| | Serum 25-OHD | Yes | Yes | | Serum calcium (total) | Yes | Yes | | Intact PTH | Yes | If baseline abnormal | | Fasting glucose | Yes | Yes | | IGF-1 | Yes | Optional | | CMP (renal function) | Yes | If on high-dose D |

What the Evidence Does Not Support

Two claims occasionally circulate in peptide-community forums that the published record does not support.

First, AOD-9604 does not raise IGF-1. The METAOD006 trial confirmed no significant change in serum IGF-1 at any dose tested over 24 weeks. [11] This distinguishes it from full-length GH and means the IGF-1-related calcium-metabolism concerns sometimes raised with GH therapy do not apply here.

Second, vitamin D does not "amplify" AOD-9604's lipolytic effect in humans. The VDR and ADRB3 pathways are distinct. No human trial has examined combined AOD-9604 plus vitamin D supplementation as a co-intervention. Claims of synergistic fat loss from this combination are not supported by evidence as of the publication date of this article.

Special Populations

Patients With Obesity

Body-fat percentage inversely predicts serum 25-OHD. A 2012 study in Clinical Endocrinology (N=400) found that each 10% increase in body-fat percentage was associated with a 4.2 ng/mL decrease in 25-OHD, independent of sun exposure or dietary intake. [13] Patients using AOD-9604 for adipose modulation should anticipate needing higher vitamin D repletion doses before their levels normalize.

Patients With Kidney Disease

CYP27B1 (the renal 1-alpha-hydroxylase) is impaired in chronic kidney disease (CKD), reducing conversion of 25-OHD to active calcitriol. These patients may need activated vitamin D analogs (e.g., calcitriol 0.25-0.5 mcg daily) rather than cholecalciferol. CKD also affects peptide clearance, and AOD-9604 use in stages 3-5 CKD lacks any published safety data. Prescribers should exercise caution in this group.

Patients on Anticoagulants

High-dose vitamin D (above 4,000 IU/day) may modestly potentiate warfarin anticoagulation through effects on vitamin K-dependent clotting factors. INR should be checked within 4-6 weeks of initiating or substantially increasing vitamin D in a patient on warfarin. AOD-9604 does not affect coagulation pathways.

What to Do If You Are Already Taking Both

If you are already taking vitamin D alongside AOD-9604, no immediate action is required to change that practice. The combination carries no known interaction risk. The practical steps are:

1. Confirm your serum 25-OHD has been checked within the past 6 months.
2. If 25-OHD is below 30 ng/mL, discuss repletion dosing with your prescribing clinician using the Endocrine Society thresholds above. [9]
3. Take your vitamin D supplement with your largest meal of the day, separate from the AOD-9604 injection timing by default.
4. Recheck 25-OHD and serum calcium at 12 weeks if you change your vitamin D dose.
5. Report any new symptoms of hypercalcemia (nausea, polyuria, fatigue, muscle weakness) to your provider promptly, as these are unrelated to AOD-9604 but can occur with vitamin D over-supplementation.

Serum 25-OHD at 12 weeks after initiating repletion should reach at least 30 ng/mL, with an optimal clinical target of 40-60 ng/mL based on current Endocrine Society guidance. [9]